Navigation Links
Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint

LONDON, March 19, 2007-AstraZeneca today announced that its collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) revealed first results from the ARISE (Aggressive Reduction of Inflammation Stops Events) phase III clinical outcomes trial which studied AGI-1067, an investigational anti-atherosclerotic agent with antioxidant and anti-inflammatory effects, in patients with coronary artery disease (CAD).
The ARISE trial did not meet its primary endpoint of a statistically significant relative risk reduction in a composite cardiovascular endpoint of CV death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, use of coronary revascularisation and for angina pectoris with objective evidence of ischemia.

AstraZeneca and AtheroGenics will now work together to fully analyse the full data set for AGI-1067, including these first results. After completion of the final analysis, under the terms of the licence and collaboration agreement AstraZeneca has a 45-day period in which to decide whether or not to continue with the collaboration.

-Ends-
19 March 2007

Media enquiries:
Patricia O’Connor, Tel: +46 708 46 76 33
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033

Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Jörgen Winroth, Tel: +1 (212) 579 0506
Ed Seage, Tel: +1 302 886 4065
Notes To Editors
The ARISE study
ARISE was a double-blind, randomised, placebo controlled study which involved more than 6,000 patients with coronary artery disease from over 250 centres in Canada, South Africa, the UK and the US. The study was designed to evaluate the additional benefits of adding AGI-1067 to current standard of care therapies, on several outcomes due to coronary vascular events such as death, heart attack, str
'"/>




Page: 1 2

Related medicine technology :

1. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
10. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... 21, 2011 MicroAire Surgical Instruments ... for carpal tunnel syndrome.  MicroAire,s new device, called ... assembly that allows surgeons to treat carpal tunnel ... wrist – thereby avoiding full open-hand surgery through ...
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
Cached Medicine Technology:MicroAire Introduces New SlimLine™ ECTR Cannula 2
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
(Date:4/22/2014)... 22, 2014Hemoglobin A1c is the standard measurement for assessing ... levels of A1c are typically measured every few months ... data-based model that accurately estimates A1c using self-monitored blood ... & Therapeutics ( DTT ), a peer-reviewed journal ... available free on the DTT website at ...
(Date:4/22/2014)... April 2014. The latest scientific advances and emerging therapies ... 2014, the main annual meeting of the Heart Failure ... Journalists will also hear breaking news on acute heart ... Failure, which is part of the main congress. , ... Greece, at the Megaron Athens International Conference Centre (MAICC). ...
(Date:4/22/2014)... at the University of Utah (U of U) has ... separate cases, U of U researchers and their colleagues ... Journal of Human Genetics . The software, Phevor (Phenotype ... unknown gene mutations by analyzing the exomes, or areas ... made, in individual patients and small families. , ...
(Date:4/22/2014)... Nearly 7 in 10 Americans support mandated coverage of ... by researchers at the University of Michigan Health System. ... age of 18 at home, and adults with private ... adults to support universal coverage of birth control medications, ... Journal of the American Medical Association ( JAMA ...
Breaking Medicine News(10 mins):Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2
... BOULDER, Colo., Aug. 25 Bioelements has ... www.ro o m214.com ) to support research, ... and online initiatives. "Room 214 was chosen as our ... consumer behavior," said Callie Lushina, Vice President of Marketing for ...
... , , Says Damage ... , , WASHINGTON, Aug. 25 The ... ) board to remove CEO John Mackey as Chairman and to begin ... Foods, lead independent director, Dr. John Elstrott, yesterday afternoon. Citing the ...
... ... across the nation take a collective step to improve their health through exercise and increased ... that may unlock the secret to living longer and healthier lives. , ... Cambridge, MA (Vocus) August 25, 2009 -- This ...
... CINCINNATI, Aug. 25 HealthWarehouse.com, Inc. (OTC Bulletin Board: ... financial results for the second quarter ended June 30, 2009. ... heavy growth in prescription sales and pharmacy transfers. Gross margins ... quarter was $396,271. , , "Consumers are ...
... , LOUISVILLE, Colo., Aug. 25 According ... Reconstructive Surgery Journal , the official journal of the American ... to be a safe and effective treatment option for fat ... Lipo to be an enhanced fat removal and transfer system ...
... in unpasteurised food has been detected in unusually high ... with the condition pre-eclampsia. These results are important ... indicator of pre-eclampsia and may help scientists to understand ... Scientists at the University of Leeds took blood ...
Cached Medicine News:Health News:Bioelements Selects Room 214 as Their Social Media and Online Marketing Agency 2Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 2Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 3Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 4Health News:Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 2Health News:Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 3Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 2Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 3Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 2Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 3Health News:New link between pre-eclampsia and diet 2
... time-consuming tasks and delivers consistently ... productivity and ensure testing accuracy ... offers automated reticulocyte counts and ... excellent sensitivity, specificity and efficiency ...
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... bi-polar CryoCor CryoBlator Series of Cryoablation Catheters ... catheter design with the two-stage cooling system ... maximize the delivery of cryoenergy to the ... work together to create the transmural lesions ...
... 5 software, the latest from Quality ... management application designed specifically for implementing ... system. The superior design, functionality, security, ... tool for managing a quality program., ...
Medicine Products: